Hypercalcemia following discontinuation of denosumab therapy: A systematic review
Denosumab is a monoclonal antibody that has been approved to treat osteoporosis, skeletal metastasis, and giant cell tumor of bone in skeletally mature patients. Due to its potential adverse effects on normal bone growth, its use has not yet been approved in skeletally immature patients; however, th...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Elsevier
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/fd67b69514304e609ca96a677fff2bf5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|